The Unfinished Science of Boxed Drug Warnings
-
By
-
John G. Rizk
-
John C. Lewin
-
May 22, 2026
-
Clinical Scorecard: The Incomplete Understanding of Boxed Warnings for Medications
At a Glance
| Category | Detail |
|---|
| Condition | |
| Key Mechanisms | Boxed warnings as a serious safety alert mechanism by the FDA |
| Target Population | |
| Care Setting | |
Key Highlights
- 30% relative reduction in montelukast initiation after the boxed warning
- Boxed warnings are the FDA's most serious safety alert
- Montelukast's boxed warning is drug-specific, not class-wide
Guideline-Based Recommendations
Diagnosis
Management
- Reserve montelukast for patients with refractory symptoms or those who do not improve with other therapies
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Patients with asthma and allergic rhinitis
Prescribing behavior may be influenced by perceived risks and benefits
Clinical Best Practices
Related Resources & Content
